INTRODUCTION
HIV-1 and SIV are lentiviruses that utilize a type-C-like retroviral strategy for morphogenesis. The precise molecular mechanisms that achieve virion assembly, budding, and maturation are still largely unknown. As with other oncoviruses and lentiviruses, the HIV-1 and SIV Gag polyproteins in the absence of other viral proteins are sufficient for the assembly and budding of VLPs Shioda and Shibuta, 1990; Wills and Craven, 1991) However, several other viral molecules, including glycoproteins, enzymes, and RNA, are required for the production of infectious particles. HIV-1 and SIV Gag polyproteins assemble into immature virions during budding and are subsequently cleaved by the viral protease to produce mature virions containing the processed Gag subunit proteins: matrix (MA), capsid (CA), nucleocapsid (NC), and p6 (Henderson et al., 1998; Mervis et al., 1988) .
The HIV-1 MA protein is modified by the addition of a myristic acid moiety at an N-terminal glycine. It has been shown that this modification plus other downstream sequences are responsible for the targeting of MA to the plasma membrane (Bryant and Ratner, 1990; Freed et al., 1994; Lee and Linial, 1994; Spearman et al., 1994; Zhou et al., 1994) . Mutations in the HIV-1 MA protein can redirect particle formation to internal cellular compartments (Facke et al., 1993; Freed et al., 1994; Gallina et al., 1994; Chazal et al., 1995) . MA also contains a nuclear localization signal which targets the viral preintegration complex to the nucleus after viral penetration (Bukrinsky et al., 1993) . In addition, HIV-1 MA was shown to be responsible for the specific incorporation of viral glycoproteins into viral particles (Yu et al., 1992; Facke et al., 1993; Wang et al., 1993; Lee and Linial, 1994) .
Regions within the central and C-terminal portions of HIV-1 MA were shown to be important for efficient particle assembly and release (Freed et al., 1994; Wagner et al., 1994; Chazal et al., 1995) . In an MuLV system, it was shown that wild-type MuLV Gag could coassemble with a chimeric Gag containing either heterologous MA or heterologous CA, suggesting that either protein could mediate Gag±Gag interactions necessary for particle production (Deminie and Emerman, 1993) . It was reported that MA protein of SIV of sooty mangabeys (SIV smm ), in the absence of other viral molecules, was sufficient to direct the release of VLPs (Gonzalez et al., 1993; Liska et al., 1994) .
We hypothesized that HIV-1 MA, independent of all other viral proteins, would be capable of directing the protein±protein interactions necessary for the assembly and release of VLPs. We expressed HIV-1 Gag-Pol, HIV-1 MA alone, or SIV MA alone, in a eukaryotic expression system. Using metabolic labeling of recombinant proteins, sucrose density gradients, and a protease protection assay, we found that HIV-1 MA alone was incapable of forming VLPs. Interestingly, employing these same methodologies, we confirmed that SIV MA was sufficient for the assembly and release of VLPs.
RESULTS
Recombinant HIV-1 MA protein was released from cells and pelleted through a 20% sucrose cushion
To confirm recombinant protein expression, the recombinant vaccina vectors, V V:gag (HIV-1), rVVmatrix (HIV-1), or rV V/SC11, were inoculated onto H9 cells, and the cultures were metabolically labeled with 3 Hleucine overnight. Cell lysate supernatants or lysed viral pellets were immunoprecipitated and separated by SDS±PAGE. In the cell lysate supernatants from VV: gag (HIV-1) infected cells, we detected the Gag polyprotein (p55), the p41 processing intermediate, and the mature products, p24 capsid (CA) and p17 matrix (MA) (Fig. 1 ). In the cell lysate supernatant of cells infected with the rVVmatrix (HIV-1) construct, high levels of a 17-kDa protein consistent with MA were observed. In the pellets derived from the culture media of VV:gag (HIV-1) infected cells, predominantly CA was detected but MA was also observed. The pellets from the rVVmatrix (HIV-1) construct contained the 17-kDa immunoreactive protein corresponding to MA. In other experiments, 3 H-myristic acid was employed for metabolic labeling. For VV:gag (HIV-1), the Gag polyprotein, the p41 intermediate, and the 17-kDa MA protein were myristylated and, as expected, CA was not (Fig. 2) . For rVVmatrix (HIV-1), the 17-kDa MA protein was myristylated. These results indicated that VV:gag (HIV-1) and rVVmatrix (HIV-1) expressed posttranslationally modified HIV-1 Gag or MA proteins with the expected electrophoretic mobilities. Furthermore, these recombinant HIV-1 Gag or MA proteins were released into media and pelleted through a sucrose cushion.
We also wished to analyze and confirm SIV MA alone assembly using the same methodologies we were applying to HIV-1 MA alone. CV-1 cells were infected with rVVp17 (SIV) and labeled with 3 H-leucine to demonstrate SIV MA expression. A 16-to 17-kDa protein was observed in both the cell lysate supernatant and in the culture medium (data not shown).
The released HIV-1 MA protein failed to enter a sucrose density gradient
To determine whether the MA proteins that were expressed by rVVmatrix (HIV-1) or rVVp17 (SIV) assembled into VLPs, density gradient centrifugation was employed. H9 cells were infected with rVVmatrix (HIV-1), VV:gag (HIV-1), or control. CV-1 cells were infected with rVVp17 (SIV) or VV:gag (HIV-1). After an overnight labeling period, the media were filtered, layered over a 20±60% sucrose gradient, and centrifuged. For VV:gag (HIV-1) infection of H9 cells, MA and CA migrated into the gradient and were localized to fractions 8±12 (Fig. 3a) . The average of the measured densities of these fractions was 1.15 g/ml, similar to that reported for HIV-1 VLPs (Shioda and Shibuta, 1990 MA expressed by rVVp17 (SIV) in CV-1 cells, as expected based on the previous work in CV-1 cells of Gonzalez et al. (1993) migrated into the sucrose gradient (Fig. 3c) . The 17-kDa bands localized to fractions 9±11, the average density of which was 1.12 g/ml. Low-density VLPs have also been reported following expression of mutant HIV-1 gag genes that lacked the I domain (Sandefur et al., 1998) . These sucrose gradient results indicated that while recombinant HIV-1 Gag or SIV MA formed VLPs, recombinant HIV-1 MA alone did not form VLPs in either H9 or CV-1 cells. However, it remained possible that aberrant membrane-bound particles formed by HIV-1 MA might be of insufficient density to penetrate the gradient or that the protein in fraction 17 was due to aggregated particles. It was also possible that the apparent low-density VLPs of SIV MA were protein aggregates or incompletely enveloped particles.
Expression of HIV-1 Gag, but not HIV-1 MA alone, produced membrane-bound particles which were trypsin resistant
To further investigate whether the proteins which were expressed by rVVmatrix (HIV-1), VV:gag (HIV-1), or rVVp17 (SIV) assembled as membrane-bound particles, we performed trypsin protection assays. After metabolic labeling, the culture medium was clarified, filtered, and divided into six aliquots. The first aliquot remained untreated, the second received trypsin inhibitor, the third received triton X-100, the fourth received trypsin, the fifth received trypsin and triton X-100, and the sixth received trypsin and trypsin inhibitor. After an incubation period, trypsin inhibitor was added, and the samples were lysed, immunoprecipitated, and analyzed by SDS±PAGE. Trypsin inhibitor alone, triton X-100 alone, or untreated samples served as controls. MA produced by VV:gag was released into the media and had an approximate molecular mass of 17 kDa: see lanes 1±3 under Gag-Pol (Fig.  4) . After treatment of the VV:gag media with trypsin (lane 4), the MA protein still migrated at 17 kDa, indicating that it had been protected from trypsin digestion by a lipid bilayer. However, when trypsin and triton x-100 were added together, so that lipid bilayers were disrupted by the detergent, the 17-kDa protein was not observed and a new cleavage product of lower molecular mass was seen (lane 5). These results indicated that VV:gag released MA proteins as components of membrane bound VLPs. It was also of interest that the Gag processing intermediate, p41, was degraded by trypsin in the absence (lane 4) or presence (lane 5) of triton X-100, confirming the sucrose gradient data (Fig. 3a) , which indicated this protein was released in soluble form. This p41 proteolysis was specific to the activity of trypsin because aliquots treated with trypsin inhibitor as well as trypsin maintained the 41-kDa protein (lane 6). Interestingly, the p24 CA protein, unlike MA, did not undergo proteolysis in the presence of trypsin and triton X-100 (lane 5). This was probably due to poor exposure of the single potential dibasic trypsin cleavage site present in the CA of HIV-1 HXB2.
In contrast, the 17-kDa protein corresponding to HIV-1 When this assay was performed on the SIV MA expressed by rVVp17 (SIV), it was found that trypsin did not cleave the MA protein even in the presence of detergent (data not shown). This was probably due to SIV MA protein folding, causing inaccessibility of the cleavage sites to trypsin or to absence of one dibasic site which was present in HIV-1. Therefore, trypsin was not useful for assessing the membrane envelopment of the released SIV MA. When the experiment was repeated with a different protease, useful data were obtained (see below). The overall results from this set of experiments provided strong evidence that the HIV-1 MA protein, expressed in the absence of other HIV-1 proteins, was unable to assemble and release VLPs.
Expression of SIV MA alone produced membranebound particles which were resistant to proteinase K To obtain definitive data on whether or not SIV MA alone formed VLPs, we employed a different enzyme in the protease protection assay. Since trypsin was not useful, proteinase K and the protease inhibitor, phenylmethylsulfonylfluoride (PMSF), were utilized. CV-1 cells were infected, labeled, and clarified. The filtered medium was treated as follows: the first aliquot was untreated, the second received PMSF, the third received triton X-100, the fourth received proteinase K, the fifth received proteinase K and triton X-100, and the sixth received proteinase K and PMSF. After the incubation period, PMSF was added and the samples were lysed, immunoprecipitated, and analyzed by SDS± PAGE. Medium from V V:gag (HIV-1) infected cells was used as a positive control and results similar to those for trypsin were obtained, except that CA in Aliquot 5 was digested by proteinase K, which cleaves peptide bonds with much less specificity than does trypsin (data not shown). SIV MA produced by rV Vp17 (SIV) was released into the media and had an approximate molecular mass of 16±17 kDa (lanes 1±4 and lane 6, Fig. 5 ). After treatment with proteinase K (lane 4), the SIV MA protein of 16±17 kDa was still present, indicating that it was protected from proteinase K digestion by a lipid bilayer. However, when proteinase K and triton X-100 were added together, disrupting the lipid layer bilayer, the 16±17 kDa protein disappeared (lane 5). These results indicated that rV Vp17 (SIV)-infected cells released SIV MA proteins as components of membrane bound particles, thereby confirming that SIV MA can form VLPs.
FIG. 4.
Trypsin protection assays indicating HIV-1 Gag, but not HIV-1 MA alone, assembled into lipid bound particles. H9 cells infected with rV Vs were labeled with 3 H-leucine overnight. The medium were filtered and split into six aliquots. Reagents were added to each aliquot as follows: Aliquot 1, untreated; Aliquot 2, trypsin inhibitor at a 500 g/ml final concentration; Aliquot 3, triton x-100 to 1%; Aliquot 4, trypsin at a 200 g/ml final concentration; Aliquot 5, triton x-100 to 1% and 200 g/ml trypsin; and Aliquot 6, 200 g/ml trypsin and 500 g/ml trypsin inhibitor. After 30 min, trypsin inhibitor was added to the tubes that had not received it to stop reactions. The media fractions were immunoprecipitated followed by SDS±PAGE and autoradiography.
DISCUSSION
As demonstrated above by metabolic labeling, density gradient centrifugation, and protease protection, recombinant expression of HIV-1 gag-pol resulted in Gag synthesis with posttranslational modification, polyprotein processing, and production of membrane bound VLPs of appropriate density. Similarly, recombinant expression of HIV-1 MA alone in the absence of other HIV-1 proteins resulted in a 17-kDa immunoreactive protein that was released into the culture medium, pelleted through a 20% sucrose cushion, and was posttranslationally modified with myristic acid. These results initially suggested that the HIV-1 MA alone might be sufficient for the assembly and release of VLPs, as had previously been described for SIV smm (Gonzalez et al., 1993; Liska et al., 1994) . However, when the culture medium from cells expressing HIV-1 MA alone was layered over a sucrose density gradient, most of the MA protein failed to enter into the gradient. These data were consistent with two interpretations: (1) the released HIV-1 MA protein was in soluble form and so failed to penetrate the gradient or (2) the HIV-1 MA protein was released within aberrant membrane bound VLPs possessing insufficient density to enter the gradient. The small amount of HIV-1 MA which pelleted completely through the 20±60% density gradient was likely an artifact; i.e., an aggregation of soluble MA protein or VLPs or MA protein associated with lysed cellular fragments.
To permit direct comparison of our HIV-1 MA results with SIV MA, recombinant expression of SIV MA alone was also performed utilizing these systems, and resulted in an immunoreactive protein of 16±17 kDa that was released into the culture medium and pelleted through a sucrose cushion. The density gradient analysis of culture medium obtained from cells expressing SIV MA alone revealed that this 16±17 kDa immunoreactive protein migrated into the gradient to a density of 1.12 g/ml.
To determine which of the possible interpretations cited above for the HIV-1 MA data were correct, a trypsin protection assay was utilized. In this experiment, MA and CA released into the medium of cells expressing the complete HIV-1 gag and pol genes were protected against trypsin digestion, indicating Gag has assembled into particles surrounded by a lipid bilayer. In contrast, the HIV-1 MA protein expressed alone and released into cell culture medium was susceptible to trypsin digestion even in the absence of detergent and therefore was not present in membrane bound particles. Taken together with the density gradient results, these trypsin protection data clearly indicated that HIV-1 MA protein alone was incapable of assembling into VLPs.
This conclusion for HIV-1 MA differed from two previous reports which also employed vaccinia expression but indicated that SIV smm MA was sufficient for the assembly and release of VLPs (Gonzalez et al., 1993; Liska et al., 1994) . The SIV MA density gradient data that we obtained appeared to confirm those results. To be certain, the trypsin protection assay was employed, but it was discovered that trypsin did not cleave the SIV MA particles even in the presence of detergent. Therefore, proteinase K was utilized in the protection assay, and it was observed that the SIV MA VLPs were protected from proteolysis unless detergent was added. Thus SIV MA alone was capable of forming low density VLPs in the absence of other viral proteins.
Why was HIV-1 MA incapable of assembly into VLPs while SIV MA was capable of forming particles? One possibility is that the assembly requirements for HIV-1 MA differ from those for SIV MA. Several residues that were shown to be important for the proper folding of SIV mac MA are altered in HIV-1 (Rao et al., 1995) . These include the glycine-45 and alanine-47 of SIV MA which may be involved in the hydrogen bonding responsible for trimerization of MA. In HIV-1 MA, these residues are alanine-45 and asparagine-47, respectively. HIV-1 MA also has one less cysteine and methionine than SIV MA, which might also affect its conformation and make it less likely to form tight self-associations. The HIV-1 and SIV smm MA proteins also have very little sequence similarity in their C-terminal regions, and FIG. 5. Proteinase K protection assay indicating SIV MA assembled into lipid bound particles. CV-1 cells infected with rV Vp17 (SIV) were labeled with 3 H-leucine for 4 h, fresh medium was added, and labelling was continued overnight. The medium was filtered and split into six aliquots. Reagents were added to each aliquot as follows: Aliquot 1, untreated; Aliquot 2, PMSF at a 2.5 mg/ml final concentration; Aliquot 3, triton X-100 to 1%; Aliquot 4, proteinase K at 10 g/ml final concentration; Aliquot 5, triton X-100 to 1% and 10 g/ml proteinase K; Aliquot 6, 10 g/ml proteinase K and 2.5 mg/ml PMSF. After 1 h at 37°C, PMSF was added to the tubes that had not received it to stop reactions. The media fractions were immunoprecipitated followed by SDS±PAGE and autoradiography.
this region could play a role in the self assembly of these proteins.
Interestingly, it was shown by deleting the entire MA coding sequence that MA may be dispensable for particle formation by HIV-1 Gag (Franke et al., 1994; Lee and Linial, 1994) . However, smaller mutations within HIV-1 MA disrupted particle formation (Freed et al., 1994; Wagner et al., 1994; Chazal et al., 1995) . Small mutations in SIV MA which could possibly change its conformation were also shown to abolish particle formation in the context of Gag (Gonzalez et al., 1996) . It appears that the contributions of MA to particle assembly depend on MA conformation. SIV smm MA may assemble without the aid of the other Gag components because its conformation permits more efficient selfassociation than occurs with HIV-1 MA. Despite the fact that in some systems the Gag proteins of HIV-1 and SIV may bind together (Franke et al., 1994) , the requirements for their MA association and assembly appear to be different. Our results with HIV-1 and SIV clearly indicate that self-assembly of MA into VLPs is not a general feature of the primate lentiviruses.
MATERIALS AND METHODS

Cells and viruses
The human T-cell lymphoma cell line, H9, was maintained in RPMI supplemented with 12% fetal bovine serum (FBS). The simian cell line, CV-1, was maintained in DMEM supplemented with 12% FBS. The recombinant vaccinia virus (rV V) constructs utilized were V V:gag (provided by the NIH AIDS repository, catalog No. 405, contributed by Edgar Engleman), rVVmatrix (HIV-1) (provided by Connie Bergman, USC), rV Vp17 (SIV smm ) (provided by Silvia Gonzalez; designated v-p17gag in Gonzalez et al., 1993) , and rVV/SC11, a control recombinant which expresses the lacZ gene (Owens and Compans,1989) . The cloning strategy for V V:gag was described (Gowda et al., 1989) . This construct expresses the Gag and Pol proteins of HIV-1 HXB2. rV Vmatrix (HIV-1) was created using PCR amplification from the cDNA for the HXB2 strain of HIV-1 using the following primers: 5Ј-5Ј-CTCTGCGCTAGC-CGCCATGGGTGCGAGAGCGTC; and 3Ј-5Ј-CGGGGCC-TCGAGACTAGTTAATTAGTAATTTTGGCTGAC. This strategy results in a stop codon being placed directly after the codon for the last amino acid of MA, the p17/p24 cleavage site. The PCR products were cut with NcoI/ SpeI and inserted into the pK vector, a previously described derivative of the pSC11 plasmid (Bergman et al., 1993) . The recombinant virus was constructed through homologous recombination using the WR strain of vaccinia (Connie Bergman, personal communication). This construct expresses HIV-1 MA in the absence of other HIV-1 proteins. The cloning strategy for the rV Vp17(SIV) has been described (Gonzalez et al., 1993) . This construct expresses SIV smm MA in the absence of other SIV viral proteins. Stocks of the vaccinia viruses were grown in either TK-or BHK-21 cell lines maintained in DMEM supplemented with 12% FBS. These stocks were titered in CV-1 cells.
Protein expression, labeling, and immunoprecipitation H9 cells were infected with the HIV-1 or control rV Vs in serum-free RPMI at a multiplicity of infection (m.o.i.) of 8 plaque-forming units (pfu)/cell. After 2 h the media was removed after a low-speed centrifugation and the cells were incubated for 30 min in leucine-free Eagle's medium. Cultures were then labeled for 4 h with 200 Ci/ml 3 H-leucine in Eagle's medium. Fresh leucinefree media and RPMI supplemented with 12% FBS (complete media) were added at a ratio of 3:1, and labeling was continued overnight. The final concentration of complete media was 20%. CV-1 cells were infected with HIV-1 Gag, HIV-1 MA, SIV MA, or control rV Vs in serum free DMEM at a m.o.i. of 8 and treated as above. All incubations were done at 37°C. Alternatively, H9 cells in RPMI were infected with the HIV-1 or control rV Vs at an m.o.i. of 5 for 2 h, then washed and labeled overnight with 3 H-myristic acid. The media from these cultures was then layered over a 20% sucrose cushion and centrifuged in an ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA) using an SW41 ti rotor (Beckman Instruments) at 125,000 g for 3 h to pellet virus-like particles. The pellets were resuspended in lysis buffer (1% triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 10 mM EDTA). The cells were subjected to lowspeed centrifugation and lysed with lysis buffer. HIV-1 or SIV proteins in media, pellets, or cell lysate supernatants were immunoprecipitated overnight at 4°C with rotation using protein A-agarose beads and pooled sera from HIV-1 infected patients or SIV infected monkeys. The beads were collected by lowspeed centrifugation, washed twice with lysis buffer, and boiled for 10 min in reducing buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 50 mM Tris-HCl pH 6.8, 0.1% bromphenol blue). The proteins were separated on 11.5 or 15% SDS±PAGE gels and visualized by autoradiography.
Density gradient centrifugation
Culture media from infected H9 or CV-1 cells were clarified by low-speed centrifugation for 5 min and filtered through 0.45-m filters. The clarified media were layered over 20±60% linear sucrose gradients and centrifuged at 125,000 g for 3 h using an SW41 ti rotor. Gradient fractions were collected from the top and diluted with lysis buffer. Density measurements with a refractometer (Bausch & Lomb) were taken before dilu-tion. The samples were then immunoprecipitated and analyzed as above.
Protease protection assay
Cultures of 5 ϫ 10 6 H9 or CV1 cells were infected with V V:gag (HIV-1), rV Vmatrix (HIV-1), rV Vp17 (SIV), or the control rV V at an m.o.i. of 8 and labeled as above. After the overnight labeling period, the cells were collected and treated as above with lysis buffer. The culture media were filtered, and each was divided into six equal aliquots and treated following a method previously described (Wills et al., 1989) . The first aliquot received no further treatment. The second aliquot received soybean trypsin inhibitor (Sigma, Inc., St. Louis, MO) to a final concentration of 500 g/ml or 2.5 mg/ml PMSF (Sigma). The third aliquot received triton x-100 to 1%. The fourth aliquot received trypsin to a final concentration of 200 g/ml or proteinase K to a final concentration of 10 g/ml. The fifth aliquot received both triton X-100 to 1% and trypsin (200 g/ml) or proteinase K (10 g/ml). The sixth aliquot received trypsin (200 g/ml) and an excess of trypsin inhibitor (500 g/ml) or proteinase K (10 g/ml) and an excess of PMSF (2.5 mg/ml). The trypsin samples were then incubated at room temperature for 30 min, after which trypsin inhibitor was added to all samples that did not previously receive it. The proteinase K samples were incubated at 37°C for 1 h, after which PMSF was added to all samples that did not previously receive it. Lysis buffer or 5x was added to all samples, followed by immunoprecipitation, SDS±PAGE, and autoradiography as above.
